Licensing, product acquisition, contract research, proof of concept leading to scale-up to manufacturing, joint development, supplier agreement.
Opportunity to influence treatment of many patients through many medical providers in joint use with an established therapeutic device.
Phase 1: Feasibility demonstration in 3-9 months
Phase 2: Pre-clinical evaluation
Phase 3: Clinical validation
Phase 1: Proof of concept funding/regulatory support commensurate with proposed activity
Solution Provider Help Desk:
NineSigma, representing Boston Scientific, invites proposals for a technology that offers a rapid, minimally invasive diagnostic to determine the amount of Airway Smooth Muscle (ASM) in the trachea and bronchi (or airway wall).
Boston Scientific treats more than 22 million patients each year and in 2015 invested more than US$ 876 million into research and development.
Boston Scientific’s Alair™ Bronchial Thermoplasty (BT) System treats severe persistent asthma by reducing ASM through use of heat delivered directly to the airway wall. The heat reduces the amount of muscle and therefore opens up the airway lumen. Severe asthmatics that have excessive ASM are good candidates for this therapy. The current standard of care for quantifying ASM in these patients is through a bronchoscopy procedure in which airway tissue is collected with biopsy forceps.
Boston Scientific would like to obtain a less invasive, quicker and cheaper method for measuring ASM.
Normal patients have about 5% ASM, whereas severe asthmatic patients who respond well to BT have higher ASM percentages often exceeding 15%. A less invasive method to identify patients with higher percentage of ASM is desired.
Anticipated Project Phases or Project Plan
Phase 1 – Feasibility demonstration
Phase 2 – Pre-clinical evaluation
Phase 3 – Clinical validation
Criteria for Moving from Phase 1 to Phase 2
Learn more about Boston Scientific and bronchial thermoplasty at http://www.bostonscientific.com and http://btforasthma.com/
The successful technology will:
Possible approaches might include, but are not limited to:
The following approaches are not of interest:
Your response should address the following:
Appropriate responses to this Request
Responses from companies (small to large), consultants, venture capitalists, entrepreneurs, or inventors are welcome. For example:
You represent a company or university that has demonstrated a proof of concept.
You represent a company or university that has reduced method to practice at lab scale.
You represent a company or university that has demonstrated a method ready for industrial implementation that could be adapted.
You represent a company or university that has a bench-scale demonstration ready to adapt.
You represent a university research department that has an undeveloped pathway with a high probability of success.